Binhui Biopharm announced that it has received $47.1 million in funding from Yangtze River Pharmaceutical Co., Ltd., DiNovA Venture Capital, Ming Capital, Jointown Pharmaceutical Group Co., Ltd, Hubei Provincial High and New Industry Investment Group Co., Ltd.
April 17, 2022
Share
Binhui Biopharm announced that it has received $47,100,000 in a round of funding led by Yangtze River Pharmaceutical Co., Ltd. on April 18, 2022. The transaction included participation from DiNovA Venture Capital, Ming Capital, Jointown Pharmaceutical Group Co., Ltd and Hubei Provincial Hi-tech Industry Investment.
Jointown Pharmaceutical Group Co., Ltd. is principally engaged in the wholesaling and retailing of pharmaceuticals and medical equipments. The Company is also engaged in the research, development and production of drugs, as well as the provision of relevant value-added services. The Companyâs products mainly include western medicines, proprietary Chinese medicines, Chinese medicine pieces, Chinese herbal medicines, medical equipments, health care products, cosmetics, among others. The Company mainly provides services to direct sales or franchise stores through its retailing businesses.
Binhui Biopharm announced that it has received $47.1 million in funding from Yangtze River Pharmaceutical Co., Ltd., DiNovA Venture Capital, Ming Capital, Jointown Pharmaceutical Group Co., Ltd, Hubei Provincial High and New Industry Investment Group Co., Ltd.
JOINTOWN PHARMACEUTICAL GROUP CO., LTD 
